It looks as if the market has finally recognized the potential investment opportunity NantKwest (NK) has to offer. During the past three months, NK has climbed more than 150% to hit a new 52-week high of $3.58. This strong move to the upside has been fueled by impressive data releases and presentations. The biggest move followed a company press release announcing NK’s Phase Ib data for their off-the-shelf NK, a checkpoint inhibitor, antigen stimulation through adenovirus therapy. The company reported impressive results that showed complete responses in TNBC patients who failed the standard